Fecal Occult Testing

Global Fecal Occult Testing Market to Reach US$1.3 Billion by 2030

The global market for Fecal Occult Testing estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Guaiac FOB Stool Test, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$488.6 Million by the end of the analysis period. Growth in the Immuno-FOB Agglutination Test segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$293.1 Million While China is Forecast to Grow at 6.8% CAGR

The Fecal Occult Testing market in the U.S. is estimated at US$293.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$268.3 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Fecal Occult Testing Market – Key Trends & Drivers Summarized

Why Is Fecal Occult Testing Gaining Market Traction? The Growing Focus on Early Disease Detection

Fecal occult blood testing (FOBT) is becoming a key diagnostic tool for detecting colorectal cancer, gastrointestinal (GI) disorders, and internal bleeding at an early stage. The rising prevalence of colorectal cancer (CRC), inflammatory bowel disease (IBD), and gastrointestinal ulcers has heightened the need for non-invasive, cost-effective, and rapid screening methods, driving the adoption of fecal occult tests in hospitals, diagnostic laboratories, and at-home test kits.

How Are Technological Innovations Improving Test Accuracy & Accessibility?

Modern fecal occult testing methods, including immunochemical fecal occult blood tests (iFOBT) and high-sensitivity guaiac-based FOBT (gFOBT), offer higher specificity, faster results, and enhanced patient compliance. Additionally, the integration of AI-driven diagnostic algorithms and telemedicine platforms is enabling remote testing, digital result analysis, and AI-assisted early cancer screening, further enhancing accessibility.

What Role Do Government Screening Programs & Healthcare Policies Play in Market Growth?

Governments and health organizations worldwide, including the WHO, CDC, and European Cancer Prevention Network, are promoting routine CRC screening programs that include fecal occult blood testing. Countries with nationalized healthcare policies, such as Japan, the UK, Canada, and Australia, have mandated population-wide FOBT screenings, significantly boosting market demand.

What’s Driving the Growth of the Fecal Occult Testing Market?

The growth in the fecal occult testing market is driven by multiple factors, including rising colorectal cancer cases, increasing adoption of non-invasive diagnostics, and government-backed screening programs. The aging global population, particularly in North America, Europe, and Japan, is a major driver, as older adults are at a higher risk of colorectal and gastrointestinal diseases, necessitating frequent FOBT screenings. Additionally, the expansion of telehealth and at-home diagnostic solutions is making self-administered FOBT kits more accessible, allowing patients to conduct tests without visiting hospitals or clinics. Innovations in AI-assisted digital pathology and liquid biopsy techniques are further enhancing test sensitivity and early disease detection accuracy, ensuring better patient outcomes and reducing the burden on healthcare systems. Moreover, the growing availability of reimbursement policies for CRC screening in major healthcare markets is lowering financial barriers for patients, encouraging higher screening rates. The shift toward preventive healthcare, coupled with rising investments in early cancer diagnostics, will continue to drive market growth, making fecal occult testing a cornerstone of global colorectal cancer prevention strategies.

SCOPE OF STUDY:

The report analyzes the Fecal Occult Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Test (Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test); End-Use (Hospital End-Use, Diagnostic Center End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Abbott Laboratories
• Alfa Scientific Designs, Inc.
• Beckman Coulter, Inc. (Danaher Corporation)
• Biohit Oyj
• Bio-Rad Laboratories, Inc.
• EDP Biotech Corporation
• Eiken Chemical Co., Ltd.
• EIKEN CHEMICAL CO., LTD.
• Epigenomics AG
• Fujirebio Diagnostics, Inc.
• Helena Laboratories Corporation
• Meridian Bioscience, Inc.
• Polymedco CDP, LLC
• Quest Diagnostics Incorporated
• Quidel Corporation
• Randox Laboratories Ltd.
• Roche Diagnostics
• Siemens Healthineers AG
• Sysmex Corporation
• Wondfo Biotech Co., Ltd.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.